BerGenBio to present at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Meet BerGenBio scientists presenting their work on BerGenBio’s lead compound BGB324 in the context of aggressive and immune evasive cancers during poster session B on Monday Sep 26th 2016 between 5.15pm and 7.45pm.
The poster is entitled “BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy” and has the number B027.
For more information on AXL and EMT please click here.